Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Omsted Kim T, Despotovic J, Lambert MP. Eltrombopag for use in children with immune thrombocytopenia. Blood Adv 2018;2:454–61.10.1182/bloodadvances.2017010660Search in Google Scholar PubMed PubMed Central
2. Adams D, Sellers TS. Eltrombopag: investigation of previously reported serum discoloration and negative interference on a total bilirubin diazo method. Arch Pathol Lab Med 2016;140:391–2.10.5858/arpa.2015-0473-LESearch in Google Scholar PubMed
3. Choy KW, Wijeratne N, Doery JC. Eltrombopag: liver toxicity, kidney injury or assay interference? Pathology 2016;48:754–6.10.1016/j.pathol.2016.07.011Search in Google Scholar PubMed
4. Gounden V, Zhao Z. Eltrombopag interference in routine chemistry testing. Ann Clin Biochem 2016;53:611–4.10.1177/0004563215609372Search in Google Scholar PubMed
5. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–10.10.1016/j.ijnurstu.2009.10.001Search in Google Scholar
6. Andersen M, Petersen PH, Blaabjerg O, Hangaard J, Hagen C. Evaluation of growth hormone assays using ratio plots. Clin Chem 1998;44:1032–8.10.1093/clinchem/44.5.1032Search in Google Scholar
©2019 Walter de Gruyter GmbH, Berlin/Boston